Raghu Mirmira, MD, PhD, is the director of the Center for Diabetes and Metabolic Diseases (CDMD) at Indiana University School of Medicine. Under his leadership, the NIH-funded CDMD at IU School of Medicine strives to transform health through basic and translational research while preparing healers with enhanced opportunities in diabetes research and scientific discovery. The focus of Dr. Mirmira’s research is the pathogenesis of diabetes mellitus and the biology of the islet. His most recent areas of interest include islet stress pathways in Type 1 diabetes and how these pathways contribute to the production of neoantigens and the activation of autoimmune responses.

In this week's Homerun Slides, understanding the DIAMOND study of people with type 1 and type 2 diabetes.

Maturity-onset diabetes of the young (MODY) refers to group of monogenic subtypes of diabetes characterized by young onset (usually before 25 years) of non-insulin-dependent diabetes, beta-cell dysfunction that is inherited as an autosomal dominant trait. Mutations in at least 10 genes have been found to cause MODY; the common subtypes are due to mutations in GCK, Hepatocyte nuclear factor 1-alpha (HNF1A), HNF4A, and HNF1B. The definition of the underlying genes has resulted in the recognition of distinct clinical and physiologic subgroups of MODY with varying clinical course, prognosis, and treatment requirements. Classifications of diabetes by the ADA and the WHO recognize these discrete subtypes.

In this Exclusive Interview transcript, Raghu Mirmira talks with Diabetes in Control publisher Steve Freed during the ADA 2018 convention in Orlando about his work as type 1 diabetes researcher, beta cell replacement, and ER Stress.

In this Exclusive Interview, Raghu Mirmira talks with Diabetes in Control publisher Steve Freed during the ADA 2018 convention in Orlando about his research in type 1 diabetes, beta cell replacement, and ER Stress.

In part 1 of this Exclusive Interview, Raghu Mirmira talks with Diabetes in Control Publisher Steve Freed about the need to look at other aspects of diabetes beyond autoimmunity.

In part 2 of this Exclusive Interview, Raghu Mirmira talks with Diabetes in Control Publisher Steve Freed about the complex components that complicate the success of beta cell replacement.

In part 3 of this Exclusive Interview, Raghu Mirmira talks with Diabetes in Control Publisher Steve Freed about the two approaches from which a cure from type 1 might come.

In part 4 of this Exclusive Interview, Raghu Mirmira talks with Diabetes in Control Publisher Steve Freed about the different ways diabetes can be treated today compared to 50 years ago, and the methods of treatment that are promising for the future.

In part 5 of this Exclusive Interview, Raghu Mirmira defines ER stress and how to intervene in the development of this condition in a conversation with Diabetes in Control Publisher Steve Freed.